Neurology & Brain Disorders Clinical Trials Update: Week 33, 2026

Published August 14, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert. Blog posts are AI-drafted from ClinicalTrials.gov source data and reviewed by the editorial team. See our editorial policy for details.

A Study to Learn About the Long-Term Safety of Higher Doses of Nusinersen (BIIB058) Given as Injections to Participants With Spinal Muscular Atrophy (SMA) Who Took Part in an Earlier Nusinersen Trial (ONWARD)

This Phase 3 study focuses on people with spinal muscular atrophy (SMA) who have previously been treated with nusinersen. It explores whether higher doses of nusinersen are safe over the long term and how they may affect growth, neurological function, and mobility. The findings could lead to improved treatment options for those living with SMA by potentially enhancing outcomes and quality of life.

A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Alzheimer's Disease Agitation

This Phase 3 trial tested AXS-05, a drug aimed at reducing agitation in people with Alzheimer's disease. Agitation can be very challenging for patients and caregivers, so a safe and effective treatment could make daily life easier and more comfortable. The study involved more than 400 participants across the United States and Puerto Rico, and results are now available to help guide future care strategies.

N-AD: Orally Administered Nicotinamide Riboside Over Two Years as a Potential Disease Modifying Treatment for Alzheimer's Disease

This Phase 2 trial evaluated nicotinamide riboside, taken as a pill, in adults with early Alzheimer's disease in Norway. The goal was to see if this treatment could slow down memory and thinking problems while being safe to use over two years. If successful, this could offer a new way to modify the course of Alzheimer's disease rather than just treat symptoms.

Dexmedetomidine in the Treatment of Agitation Associated With Dementia (TRANQUILITY II)

This Phase 3 study tested a medication called BXCL501 for people experiencing episodes of agitation related to dementia. Given as needed, this treatment aims to quickly and safely calm agitation, which can be distressing for both patients and caregivers. The trial included 151 participants from across the United States, and the results may provide an additional option for managing these difficult symptoms.

A Study to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease

This Phase 2 trial is investigating CT1812, a new drug for people with early Alzheimer's disease, to determine if it is safe and if it can slow cognitive decline. The study is ongoing with participants from several US locations, and the results are expected after about 18 months. This research could help expand treatment choices for those in the early stages of Alzheimer's.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.